TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05954078
Drug: mFOLFOX6/XELOX adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles or XELOX (oxaliplatin 130mg/m2, ivgtt, Q3w; capecitabine 1000mg/m2, p.o, Q3w) for 8 cycles
Study: NCT05483439
Drug: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
Study: NCT05483439
Drug: traditional herbal medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: traditional herbal medicine
Study: NCT06539273
Drug: Exosome Complex, RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 3 mL of exosomes (2 mL to the frontal and 1 mL to the vertex region) was injected using napage technique (10¹⁰ extracellular vesicles in 1 mL)
Study: NCT04481555
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prophylactic azithromycin treatment 250 mg three times weekly vs placebo
Study: NCT04481555
Drug: ICS
Normalized name: ICSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months) vs continued LABA/LAMA/ICS treatment
Study: NCT04826185
Drug: IMB-1018972
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release (MR) oral tablet
Study: NCT04826185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral tablet
Study: NCT06387121
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alkylating agent
Study: NCT06387121
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antifolate antineoplastic drug
Study: NCT05986721
Drug: AGB101
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-dose levetiracetam, 220 mg, extended release tablet
Study: NCT05986721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet
Study: NCT05536752
Drug: QA102/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT05536752
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT05158387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
Study: NCT06047548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05558904
Drug: Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05048342
Drug: LOU064
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient took one film-coated tablet in the morning and one film-coated tablet in the evening (except the morning dose at the PK sampling visits, which were to be taken on site during the visit).
Study: NCT05922904
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT05475808
Drug: Wrist local steroid injection
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wrist local steroid injection:~After proper area cleaning with povidone solution, 1ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml) steroid injection will be applied around the median nerve with a 22 G injector from ulnar side of the wrist proximal crease under ultrasound guidance.
Study: NCT06254261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04173650
Drug: AGLE 102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exosomes from MSCs up to six administrations
Study: NCT06109818
Drug: ICP-488 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-488 Placebo will be administered as tablet
Study: NCT05012436
Drug: YHD1119 75mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose
Study: NCT06264310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo SC injection
Study: NCT05774639
Drug: Xolair Prefilled Syringe
Normalized name: Xolair Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution
Study: NCT06664502
Drug: EYE201
Approvals — FDA: no, EMA: no, PMDA: no
Description: EYE201 solution for intravitreal administration
Study: NCT06044090
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take 2 pills of 100 mg totaling a 200 mg dose of minocycline per day.
Study: NCT06044090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 2 placebo tablets matching the Minocycline tablets daily for 5 days.
Study: NCT05139602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection
Study: NCT04908423
Drug: Xeomin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: To discover whether injection into the upper extremity with Xeomin® triggers improvements in gait-related mobility and quality of life in adults with hemiparesis secondary to stroke.
Study: NCT06137482
Drug: REGN13335
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose
Study: NCT06137482
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV or SC, sequential ascending single dose
Study: NCT06117046
Drug: Cardiopeptidin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiopeptidin was administered intravenously once a day with cardiopeptidin for 3 days.The dosing regimen follows the recommended dosage of 1 mg/kg/day as outlined in the product manual, with doses calculated based on the ideal body weight.
Study: NCT05143177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-1229 Placebo, 1 tab
Study: NCT04829695
Drug: Artemether-lumefantrine drug combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
Study: NCT04983368
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo which is identical in appearance to the test product (5 mg, 10 mg Xanamem® QD) except that it contains no active ingredient.
Study: NCT04983368
Drug: Xanamem® 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Xanamem® (UE2343) capsules 10 mg, administered orally once daily.
Study: NCT05848687
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO or NG.
Study: NCT05848687
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV, IM or PO
Study: NCT05729568
Drug: Antiretroviral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide.
Study: NCT06503042
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the chemotherapy alone group use any chemotherapy drug. The premise is that the treatment regimen for patients is consistent with the diagnostic and treatment protocols.
Study: NCT05065372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical to Metformin Hcl 1000Mg Tab but without metabolic effects
Study: NCT05563675
Drug: Long acting muscarinic antagonists (LAMAs) in the evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAMAs administered at bedtime (8pm - 2am)
Study: NCT05436535
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: On Day 7, all dupilumab-naïve AD participants will apply hydrocortisone 2.5% ointment twice daily to active lesions on sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply hydrocortisone 2.5% ointment once or twice daily, per clinician discretion, to active lesions on sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI \>7) participants may apply hydrocortisone 2.5% ointment as needed to active lesions on sensitive, non-target skin.
Study: NCT05469347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo to match a 600 mg dose of alirocumab will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.
Study: NCT04438213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
Study: NCT06394167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for IV administration.
Study: NCT05738564
Drug: Epinephrine Inhalation Solution
Normalized name: Epinephrine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: epinephrine prepared solution mixed with lidocaine (EL) Otrivin adult nasal drops 0.1Otrivin adult nasal drops 0.1%, 10 ml of 1 mg/ml; Novartis Consumer Health, UK Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK) in each nostril in the pre-induction room just before the induction of anesthesia
Study: NCT04797156
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline poured on wound
Study: NCT06177041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as a minimum 2-hour IV infusion.
Study: NCT06177041
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered orally twice daily (bid).
Study: NCT05058287
Drug: Depo-Medrol 40Mg/Ml Suspension for Injection
Normalized name: Depo-Medrol 40mg/ml Suspension for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg Depo-Medrol mixed with hemostatic matrix
Study: NCT05266027
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication, Nalbuphine Sebacate not contained
Study: NCT04078139
Drug: The MP/RP group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miscible liquid of methylprednisolone and ropivacaine in this study will be peri-incisional scalp infiltration with 40mg methylprednisolone, 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
Study: NCT05181137
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets taken once daily (QD)
Study: NCT05181137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets taken once daily (QD)
Study: NCT05080660
Drug: LY3526318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05080660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00002065
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05201469
Drug: Placebo for VIB4920
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo for VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
Study: NCT04871269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05348993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05517421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT05774275
Drug: Pegylated Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: In phase Ib: 37.5 mg/m2, 30 mg/m2, d1, q3w; In phase II: recommended phase 2 dose (RP2D), d1, q3w.
Study: NCT05774275
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2, d1, q3w Doxorubicin hydrochloride will be administered if subject is allergic to Doxil.
Study: NCT05259085
Drug: ALXN2050
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
Study: NCT06475274
Drug: RMC-035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein, a recombinant variant of A1M. Concentrate for solution for infusion.
Study: NCT06475274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical to RMC-035 intervention devoid of the active substance.
Study: NCT04890431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ambient air not enriched with oxygen (5 L/minute for 30 minutes by nasal cannula, twice/day)
Study: NCT05043558
Drug: beprostaglandin sodium
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beprostaglandin sodium
Study: NCT04566666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of SCD-044 product
Study: NCT04566666
Drug: SCD-044_Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCD-044 tablets in Dose 1.
Study: NCT04566666
Drug: SCD-044_Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCD-044 tablets in Dose 2
Study: NCT05816343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at a dose of 2 capsules (each containing 60 mg placebo) three times a day with each meal (a total dose of 360 mg daily).
Study: NCT06373406
Drug: MHB036C
Approvals — FDA: no, EMA: no, PMDA: no
Description: An antibody-drug conjugate therapy
Study: NCT05479578
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05651932
Drug: Cohort A1 & A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTX-1001 will be administered orally for 28 days each cycle until progression. Dexamethasone: Orally once weekly
Study: NCT05651932
Drug: Cohort C1 & C2
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTX-1001: Orally for 28 days each cycle until progression Carfilzomib: IV, once weekly for 3 weeks in each 28-day cycle Dexamethasone: Orally once weekly
Study: NCT05651932
Drug: Cohort D
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTX-1001: Orally daily for 28 days each cycle until progression Pomalidomide: Orally, for 21 days in each 28-day cycle Dexamethasone: Orally once a week
Study: NCT05639946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo drug
Study: NCT05753033
Drug: SR750 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending single and multiple doses of SR750 orally
Study: NCT05753033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending single and multiple doses of placebo orally
Study: NCT05224141
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution administered via IV infusion on Cycle 1 (and Q3W as needed beyond Cycle 1)
Study: NCT05821712
Drug: 0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: mouthwash
Study: NCT05241431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets similar to active treatment.
Study: NCT04680676
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05443555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to this group will receive a placebo medication for 3 months and will be instructed to follow the same pill regimen as the intervention arm.
Study: NCT05802173
Drug: TDM-105795, 0.0025%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
Study: NCT05802173
Drug: TDM-105795, 0.02%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
Study: NCT06395688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo soft capsules (identical to active compound)
Study: NCT05350592
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator and diluent
Study: NCT05930951
Drug: OBT076
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBT076 is an ADC constituted by a fully human immunoglobulin 1 (IgG1) antibody directed against the CD205/Ly75 antigen (MBH1309), inducing potent cytotoxic and anti-tumor activity
Study: NCT05113394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sublingual therapy
Study: NCT04953052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An isotonic sterile solution
Study: NCT05329090
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo experimental treatment
Study: NCT06412315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of placebo (sucrose). Tablets encapsulated to aid blinding. To take per oral once
Study: NCT06513884
Drug: HB-202/HB-201 alternating 2-vector therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of HB-202 alternating with HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
Study: NCT06513884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of matched placebo for HB-202 alternating with matched placebo for HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
Study: NCT05913388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally twice daily at 100mg.
Study: NCT05482672
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The oral placebo will consist of corn starch and gelatin capsules
Study: NCT05188222
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specifically formulated placebo to provide a similar taste and texture to Maltodextrin, without the same carbohydrate characteristics
Study: NCT05613036
Drug: [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[¹⁴C\]-BI 907828 mixed with BI 907828 (formulation 1)
Study: NCT05613036
Drug: [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[¹⁴C\]-BI 907828 mixed with BI 907828 (formulation 2)
Study: NCT05843799
Drug: ILB-202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single i.v. infusion
Study: NCT05843799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single i.v. infusion
Study: NCT05223231
Drug: LBL-019 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: initial dose-MTD
Study: NCT06355531
Drug: FNP-223
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT06355531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT00021671
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06241456
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as an IV infusion at planned dose levels.
Study: NCT06530563
Drug: Sufentanil Citrate
Normalized name: Sufentanil Citrate
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil Citrate injection, specification: 50 ug/ml, 1 ml; Avoid light seal; Yichang humanwell pharmaceutical co., LTD.
Study: NCT05220800
Drug: Iron(III)isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-dependent dosage of iron(III)isomaltoside. See group descriptions
Study: NCT05220800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoton saline infusion
Study: NCT06568783
Drug: [18F]-FAPI-74
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]-FAPI-74 7 mCi ± 20% administered intravenously.
Study: NCT06218212
Drug: calcium carbonate (phosphorus binder) with / or sodium polystyrene sulfonate (potassium binder) with dosage 0.5-1mg/kg/day orally.
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium carbonate (phosphorus binder) in dosage of 45-65 mg/kg/day orally with / or sodium polystyrene sulfonate (potassium binder) in dosage of 0.5-1mg/kg/day orally.
Study: NCT06538649
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin provided at 10 mg start; 5mg for Asians. Dose will be increased to 20 mg for those tolerating and without contraindication.
Study: NCT05367336
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: third group receiving fentanyl
Study: NCT04220203
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 orally two times per day on Days 1-14 of each 21-day cycle